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Than 1,000 Collections
Peter Gambell,1 Kirsten Herbert,1 Michael Dickinson,1 Kerrie Stokes,1 Mathias Bressel,1
Dominic Wall,1,2 Simon Harrison,1,2 H. Miles Prince1,21 1The role of the peripheral blood (PB) CD34 cell count in predicting the CD34 cell yield in hematopoietic
progenitor cell apheresis collections is well established. However, sometimes unexpectedly poor CD341 cell
yields are obtained. To determine the effect, if any, of a range of factors on the ability of the PBCD341 count to
predict collection CD341 cell count, we performed a retrospective analysis on consecutive hematopoietic
progenitor cell apheresis collections between 2004 and 2008. Factors investigated included mobilization reg-
imen, PB white blood cell count, body weight, and disease. After exclusion of collections involving apheresis
complications, a total of 1,225 PB CD341 cell results with corresponding collection CD341 cell results from
458 patients were analyzed. Although differences in the median PB CD341 cell counts and collection CD341
cell counts were seen betweenmobilized collections with chemotherapy plus granulocyte colony-stimulating
factor and those with granulocyte colony-stimulating factor alone, the predictive capability of the PB CD341
cell count for the collection CD341 cell yield remained similar. Although poorer collection efficiencies were
observed in themyelodysplastic syndrome/myeloproliferative disorder diagnostic subgroup, our findings con-
firm that PB CD341 cell analysis remains a powerful and irreplaceable tool for predicting hematopoietic pro-
genitor cell apheresis CD341 cell yield.
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High-dose chemotherapy and autologous hemato-
poietic progenitor cell (HPC) transplantation is estab-
lished therapy for various hematologic cancers and
solid tumors [1-6]. With the availability of growth
factor-based mobilization regimens, peripheral blood
(PB) collections by apheresis (HPC-A) have generally
replaced bone marrow as the preferred source of
HPCs [7]. HPC-A collection has proven to be more
convenient, safer, and more cost-effective while dem-1Peter MacCallum Cancer Centre, Melbourne, Australia;
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6/j.bbmt.2011.10.002onstrating more rapid hematopoietic recovery with
lower microbial contamination rates [6-10]. However,
HPC-A collection and cryopreservation remains
a resource-consumptive procedure. Cost analyses
vary, but the reported cost range in one study was
US $9,987-$26,263 per patient for the evaluation,
mobilization, harvesting, and cryopreservation phases
alone [11]. The wide variation in cost is explained
in part by the variability in number of collections
per patient. Thus, reliable prediction of the HPC-A
is a valuable tool to minimize costs by avoiding
unnecessary collections.
Detection of the CD34 antigen on the surface of
leukocytes has proven to be a reliable surrogate marker
for identification of self-renewing, pluripotent HPCs
and has generally replaced the cumbersome colony-
forming unit assay for granulocytes and macrophages
[12,13]. Assessment of apheresis products by measuring
CD341 cell counts by flow cytometry evaluates the
most primitive HPCs along with maturing, lineage-
committed progenitors. Doses .2  106 CD341
HPCs/kg of patient body weight have been found to be
predictive of both short-term and long-term hemato-
poietic recovery after high-dose chemotherapy [14,15].763
Table 1. Patient Characteristics (n 5 458)
Characteristic Patients, n (%)
Sex
Male 284 (62.0)
Female 174 (38.0)
Diagnosis
NHL 193 (42.1)
Plasma cell dyscrasias 156 (34.1)
Acute myelogenous leukemia 25 (5.5)
Hodgkin lymphoma 20 (4.4)
Myeloproliferative neoplasms 13 (2.6)
Sarcoma 11 (2.4)
Solid tumor 10 (2.2)
Chronic lymphocytic leukemia 9 (2.0)
Acute lymphoblastic leukemia 8 (2.7)
MDS 3 (0.7)
Other 10 (2.2)
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optimal timing of HPC-A collection is well established,
as is its contribution to achieving an adequate CD341
dose [16-23]. Quantitation of CD341 HPCs is
generally available within 1 hour after collection.
Moreover, the single-platform assay demonstrates low
interlaboratory and intralaboratory variability [24]. In
general, centers that use PB CD341 cells as a trigger
forHPC-A collection do not start apheresis until a min-
imumPBCD341 cell threshold is reached. At our insti-
tution, we previously showed that a PBCD341 count of
5.0  106/L reliably predicts an HPC-A product
CD341 cell count of .0.5  106/kg [22]. Thus, our
minimum CD341 cell infusion dose of 2.0  106/kg
should be obtained within a maximum of four HPC-A
collections.Despite this, PBCD341 count as apredictor
of product yield can be unreliable, and sometimes unex-
pectedly poor CD341 cell yields are obtained, referred
to as poor CD341 collection efficiency (CE). A range of fac-
tors are known to contribute to CE, including optimal
apheresis performance (instrument- and operator-asso-
ciated), patient body weight, PB WBC count (WCC),
hematocrit value, serum albumin level, diseases, and
mobilization regimen [25]. Although some of these fac-
tors are known to have an effect on mobilization effi-
ciency, their effect on CE is not well understood.
To evaluate the effect, if any, of a range of factors
on the ability of the PBCD341 count ( 106/L) to pre-
dict the collection CD341 cell yield ( 106/kg), we
performed a retrospective analysis of consecutive
HPC-A collections during the period from 2004 to
2008. Our primary aim was to determine how closely
the PB CD341 cell count predicted the HPC-A
CD341 cell yield across a range of clinical and biolog-
ical variables.We sought to confirm our previous work
(and other published data) indicating that PB CD341
count reliably predicts HPC-A CD341 cell yield, as
well as to stratify our data into a number of clinical var-
iables to assess whether these variables have a negative
affect on this predictive ability.
METHODS
Patients and Assessed Variables
A total of 1,297 HPC-A collections obtained from
458 patients during the 5-year analysis period were in-
cluded in the initial analysis. Collections that incurred
unexpected complications during apheresis, resulting
in reduced processing volume, were excluded from
analysis (n5 72). The median patient age was 55 years
(range, 17-81 years). Other patient characteristics are
summarized in Table 1.
Mobilization
The mobilization regimen for 305 patients (810
individual HPC-A collections) involved a range of che-
motherapy agents plus granulocyte-colony stimulatingfactor (G-CSF [filgrastim]; Amgen Australia, XXX),
the regimen for 153 patients (415 individual HPC-A
collections) involved filgrastim alone. The filgrastim
was administered as daily s.c. injections at a dose of
10 mg/kg. For filgrastim-alone mobilizations, filgras-
tim was started on day 1, and PB CD341 cell monitor-
ing was initiated on day 4. After the chemotherapy 1
filgrastim mobilization, filgrastim was administered
at 10 mg/kg/day starting the day after the last day of
chemotherapy. PB CD341 counts were monitored ac-
cording to expected leukocyte recovery after myelo-
suppressive chemotherapy, and HPC-A collection
was initiated once PB CD341 counts were $5 
109/L, in accordance with our unit’s policy.
Apheresis Collection
AutologousHPC-A collections were performed by
the apheresis unit under current good manufacturing
practices (cGMP) conditions (Australian Therapeutic
Goods License 149827) using Cobe Spectra (Cobe,
Denver, CO) and Haemonetics MCS1 (Baxter
Healthcare, Deerfield, IL) apheresis machines. Collec-
tion was performed until 2 blood volumes were
processed with the Spectra device (continuous pro-
cessing) or 1.5 blood volumes were processed with
the MCS1 device (discontinuous processing).
Collection episode characteristics are summarized
in Table 2. Factors analyzed for potential impact on
prediction were PB WCC (\20, 20-50, and .50 
109/L), mobilization regimen (filgrastim alone or fil-
grastim 1 chemotherapy), patient body weight (\70,
70-100, and .100 kg), and diagnosis (non-Hodgkin
lymphoma, plasma cell dyscrasia, or other).
HPC-A Cryopreservation
Autologous HPC-As were processed under cGMP
conditions within 24 hours of collection. Volume re-
duction of the initial apheresis product was performed
by centrifugation and removal of plasma and platelets.
The platelet-poor autologous plasma generated as
a byproduct of this process was used whenever possible
Table 2. Collection Frequencies (n 5 1,225)
Variable Mean Median Range Category Collections, n (%)
PB WCC  109/L 29.1 26.6 0.9-202 <20 453 (37.0)
20-50 608 (49.6)
>50 164 (13.4)
Mobilization Filgrastim alone 415 (33.9)
Filgrastim + chemotherapy 810 (66.1)
Weight, kg 78.1 78 43-136 <70 358 (29.2)
70-100 780 (63.7)
>100 87 (7.1)
PB CD34+ cells,  106/L 61.2 21.2 0.2-1980.7 Low: <20 593 (48.4)
Moderate: 20-50 281 (22.9)
High: >50 351 (28.7)
Collection CD34+ cells,  106/kg 4.04 1.48 0.01-117.8
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When insufficient autologous plasma was available,
Albumex 20 (CSL, Melbourne, Australia) was used.
The cell concentration was adjusted to result in a final
product with a total WBC concentration of\200 
106/mL. A viable CD341 cell count was performed
on this volume-reduced buffy coat, with the result re-
ported as 106/kg patient body weight. The volume-
reduced buffy coat was suspended in 10% DMSO
solution with approximately 2% protein and then
frozen at a controlled rate and stored in vapor-phase
nitrogen above liquid nitrogen until required for use.Flow Cytometric CD341 HPC Determination
Viable PB CD341 cell collection CD341 cell
counts were performed using a single-platform
method based on the ISHAGE gating strategy
[26-29] (Figure 1) using a FACSCalibur flow cytome-
ter (BD, San Jose, CA). In brief, a volume of whole
blood or buffy coat was incubated with 10 mL of
CD45 FITC (clone J33; Immunotech, Marseille,
France), 10 mL of CD34 PE (Immunotech clone
581), and 10 uL of 7AAD (Immunotech) for 15 min-
utes at room temperature in the dark. Red cells were
lysed with ammonium chloride (Immunotech) for 10
minutes. An equal volume of well-mixed FlowCount
fluorospheres (Beckman Coulter, Fullerton, CA) of
known concentration was added, and data were
acquired on the flow cytometer without washing. PB
CD341 and collection CD341 cell counts were calcu-
lated and reported as cells  106/L and cells  106/kg
body weight, respectively.
Statistical Analysis
Patient demographic data were summarized using
descriptive statistics, including the mean, median, and
range for data measured on a continuous scale and
counts and percentages for categorical data. Mobiliza-
tionwas classified into twomobilization regimengroups
(filgrastim alone vs filgrastim1 chemotherapy).Weight
was classified into three groups (\70 kg, 70-100 kg, and
.100 kg), as wereWCC count (\20 109/L, 20-50109/L, and.50 109/L), PBCD341 cell count (\20
106/L, 20-50 106/L, and.50 106/L), and diagnosis
(non-Hodgkin lymphoma [NHL], plasma cell dyscra-
sias [principally multiple myeloma (MM)], and other).
Both PB CD341 cell and collection CD341 cell counts
showed a skewed (nonnormal) distribution and thus
were transformed to the natural logarithmic scale before
any statistical models were fitted. Univariate linear re-
gression to test for associations between PB CD341
cells and collection CD341 cells was performed sepa-
rately for each category of the following factors:
mobilization regimen, weight category,WCCcategory,
and diagnosis. The goodness of fit was assessed using
R2. Regression models were compared using the c2
goodness-of-fit statistic.
Multivariate linear regression was performed on
the aforementioned variables. The final model was ob-
tained considering a stepwise procedure in which the
inclusion of a variable was assessed by the likelihood
ratio test of the nested models. The residuals were
analyzed to evaluate the adequacy of the final model.
In addition, CE was calculated using the following
formula:
Collection efficiency ð%Þ
5
Total CD341 cells obtained from apheresis
PB CD341ðulÞX apheresis process volumeðLtÞ
Collections with a PB CD341 cell count .10
 106/L and a CE\20% (arbitrarily set lower limit)
were tabulated according to the foregoing character-
istics and analyzed for possible trends that might
contribute to low CE. On these, boxplots were
drawn to demonstrate trends where relevant, with
the two-tailed Student t-test used to determine
significance.RESULTS
After elimination of 72 collections involving unex-
pected cessation or prolongation of apheresis, 1,225 PB
CD341 cell results and the corresponding collection
Figure 1. Single-platformCD34 ISHAGE-based gating strategy. Viable cells were analyzed using a gate based on 7AADexclusion. A gatewas then drawn
onCD451 cells (R1) to exclude noncellular debris and unlysed red cells. A gatewas then drawn to capture a discrete cluster of CD341 cells with low side
scatter (R2). These cells were further refined using a homogenous cluster based on intermediate CD451 cell expression (R3), and theCD341HPCs (R4)
were finally defined using intermediate forward scatter (final CD341 HPCs compared with lymphoid population follicular stem cells). The number of
events in this R4 gate were compared with the number of events counted in the singlet bead gate (R7) to derive the reported CD341 cell count.
766 Biol Blood Marrow Transplant 18:763-772, 2012P. Gambell et al.CD341 cell results (from 458 patients) were analyzed.
Summary statistics for the variables analyzed in these
1,225 samples are presented in Tables 2 through 4.Nine patients with a PB CD341 cell count .10 
106/L and CE\20% were identified; data for these
patients are presented in Table 5.
Table 3. PB and Collection CD34+ Cell Results According to Collection Variables (n 5 1,225)
Variable n
PB CD34+ Cells,  106/L Collection CD34+ Cells,  106/kg
Mean Median Range Mean Median Range
Weight, kg
<70 358 56.0 19.0 0.8-859.5 3.87 1.40 0.04-52.60
70-100 780 60.9 21.1 0.2-1980.7 3.98 1.46 0.01-117.80
>100 87 66.2 24.8 1.4-504.1 3.93 1.73 0.10-35.40
Mobilization
Chemotherapy + filgrastim 810 75.9 29.2 0.2-1980.7 5.10 2.06 0.01-117.80
Filgrastim alone 415 27.1 10.0 0.3-526.4 1.59 0.78 0.01-28.64
Pre-WCC
<20  109/L 453 62.9 21.9 0.2-1980.7 4.78 1.92 0.01-97.13
20-50  109/L 608 54.9 18.7 0.5-1608.0 3.39 1.20 0.03-117.80
>50  109/L 164 68.4 30.2 1.1-859.5 3.64 1.55 0.04-42.80
NHL 455 54.0 19.0 0.3-1980.7 3.77 1.31 0.03-97.13
Plasma cell dyscrasias 417 72.4 27.6 0.2-678.8 4.70 1.87 0.01-46.50
Other 353 57.1 19.7 0.9-1608.0 3.62 1.31 0.04-117.8
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Overall
The relationship between PB CD341 cells and
collection CD341 cell yield is illustrated in Figure 2A
and B. For all of the data analyzed, a significant linear
relationship was shown between log collection CD341
cell count and log PBCD341 cell count. The fitted rela-
tionship between log collection CD341 cell count and
logPBCD341 cell count is shown inFigure 2C, showing
that a doubling of fluorosphere PB CD341 cell count
would lead to a 20.9593 5 1.94-fold higher collection
CD341 cell count.
Log collection CD341 and log PB CD341 cell
counts and effect of mobilization
Compared with the overall model, the effect of
mobilization group (filgrastim alone vs chemotherapy
1 filgrastim) does not alter the fit. Although filgrastim
1 chemotherapy mobilization was associated with
higher PB CD341 cell counts (30.4  106/L vs 10.4 
106/L) and collection CD341 cell counts (2.1  106/kg
vs 0.8 106/kg) compared with filgrastim-alonemobili-
zation, the actual slopes are similar. The fitted regres-
sions are shown in Figure 3.
Log collection CD341 and log PB CD341 cell
counts and the effect of weight
The effect of patient body weight was analyzed
by dividing the patients into three weight categories.Table 4. PB and Collection CD34+ Cell Results According to Mobil
Variable n
PB CD34+ Cell
Mean Median
Chemotherapy + filgrastim mobilization 810
Pre-WCC <20  109/L 385 70.4 28.1
20-50  109/L 327 84.3 29.1
>50  109/L 98 88.6 35.5
Filgrastim alone mobilization 415
Pre-WCC <20  109/L 68 33.0 6.7
20-50  109/L 281 22.2 11.0
>50  109/L 66 46.5 17.8Although small differences in the mean log PB
CD341 cell and log collection CD341 cell counts
among the three weight categories was shown, the
rate of increase of did not differ significantly (ie, similar
slopes, or parallel lines). The fitted regressions between
log collection CD341 cell and log PB CD341 cell
counts according to weight categories (\70 kg vs
70-100 kg vs .100 kg) are shown in Figure 4.
Log collection CD341 and log PB CD341 cell
counts and the effect of WCC
The effect of PB WCC was analyzed by dividing
patient data into three categories of WCCs. Again,
although small differences in the mean log PB
CD341 cell and log collection CD341 cell counts
were seen among the three categories, the rate of in-
crease of log collection CD341 cells with log PB
CD341 cells did not differ significantly among the
three WCC categories (ie, similar slopes or parallel
lines). The fitted regressions between log collection
CD341 cells and log PB CD341 cells according to
WCC category (\20  109/L vs 20-50  109/L vs
.50  109/L) are shown in Figure 5.
Log collection CD341 cell and log PB CD341 cell
counts and the effect of diagnosis
The effect of diagnosis was analyzed by dividing
patients into three categories: NHL (n 5 455), MM
(n5 417), and other (n5 353). Again, although a differ-
ence in the mean and median levels of log PB CD341ization Regimen: Effect of WCC
s,  106/L Collection CD34+ Cells,  106/kg
Range Mean Median Range
0.2-1980.7 5.48 2.34 0.01-97.13
0.8-1608.0 5.15 1.87 0.05-117.80
1.7-859.5 4.96 1.98 0.04-42.79
0.3-338.2 1.75 0.52 0.01-18.01
0.5-223.0 1.45 0.82 0.03-18.18
1.3-526.4 2.24 1.07 0.05-28.64
Table 5. Collection Episodes With CE <20% and PB CD34+ >10  106/L (n 5 9)
Patient
Day of
Collection Diagnosis Mobilization
Patient
Weight, kg
Peripheral
WCC, 109/L
PB CD34+,
106/L
Collection
CD34+, 106/kg
Collection
Efficiency, %
1 First of 4 MPD Filgrastim alone 92 10.1 247.0 2.21 6.7
2 First of 3 MM Chemotherapy + filgrastim 69 3.9 67.5 1.02 10.4
3 Second of 2 MM Chemotherapy + filgrastim 53 24.6 561.9 9.77 13.2
4 Second of 2 MDS Filgrastim alone 96 56.0 340.4 5.90 13.7
5 Third of 3 MPD Filgrastim alone 91 69.8 126.1 2.22 13.9
6 First of 4 MM Chemotherapy + filgrastim 73 34.6 39.5 0.76 14.5
7 Second of 2 MPD Filgrastim alone 100 49.1 219.7 4.26 15.4
8 First of 4 NHL Chemotherapy + filgrastim 82 49.5 38.7 0.94 17.8
9 Second of 3 NHL Chemotherapy + filgrastim 67 53.5 159.5 5.10 19.9
768 Biol Blood Marrow Transplant 18:763-772, 2012P. Gambell et al.cells and log collection CD341 cells among the three
categories was demonstrated, the rate of increase of
log collection CD341 cells with log PB CD341 cells
did not differ significantly among the three diagnosesFigure 2. (A) Non–log-transformed PB CD341 cell counts versus col-
lection CD341 cell counts. (B) Non–log-transformed PB CD341 cell
counts versus collection CD341 cell counts for all samples with PB
CD341 cell count\300  106/L. (C) Relationship between collection
CD341 cell count and PB CD341 cell count for all samples (after loga-
rithmic transformation); y522.57121 0.9593x; R25 91.9%; P\.0001.(ie, similar slopes or parallel lines). The fitted regres-
sions between log collection CD341 cells and log PB
CD341 cells according to diagnosis are shown in
Figure 6.
Multivariate Modeling Considering Possible
Confounders
The relationship between PB CD341 cell and col-
lection CD341 cell counts was further investigated
considering WCC, weight, mobilization, and diagno-
sis as potential confounders. Multivariate linear re-
gression using a stepwise procedure was performed
based on the preceding simple linear regression
(Figure 2C). Mobilization and diagnosis did notFigure 3. (A) Relationship between collection CD341 cell count and
PB CD341 cell count for all samples from patients mobilized using fil-
grastim alone (after logarithmic transformation); y 5 22.5362 1
0.9234x; R2 5 89.6%; P\ .0001. (B) Relationship between collection
CD341 cell count and PBCD341 cell count for all samples from patients
mobilized using filgrastim 1 chemotherapy (after logarithmic transfor-
mation); y 5 22.5451 1 0.9597x; R2 5 91.6%; P\.0001.
Figure 4. (A) Relationship between collectionCD341 cell count and PB
CD341 cell count for all samples frompatientsweighing\70kg (after log-
arithmic transformation; y522.50591 0.9508x; R25 90.8%; P\.0001).
(B)Relationship between collectionCD341 cell count and PBCD341 cell
count for all samples from patients weighing 70-100 kg (after logarithmic
transformation; y522.6081 0.9651x; R25 92.1%; P\.0001). (C) Re-
lationship between collectionCD341 cell count and PBCD341 cell count
for all samples frompatientsweighing.100 kg (after logarithmic transfor-
mation; y 5 22.5518 1 0.9466x; R2 5 94.9%; P\.0001).
Figure 5. (A) Relationship between collection CD341 cell count and
PB CD341 cell count for all samples from patients with WCC\20 
109/L (after logarithmic transformation; y 5 22.4500 1 0.9681x; R2
5 92.1%; P\ .0001). (B) Relationship between collection CD341 cell
count and PB CD341 cell count for all samples from patients with
WCC 20-50  109/L (after logarithmic transformation; y 5 22.6110
1 0.9538x; R25 93.7%; P\.0001). (C) Relationship between collection
CD341 cell count and PB CD341 cell count for all samples from patients
withWCC.50 109/L (after logarithmic transformation; y522.7725
1 0.9589x; R2 5 90.4%; P\.0001).
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ables, and the final multivariate model obtained was
logðCollCD34Þ522:81710:962 logðPB CD34Þ20:186
 logðWCCÞ20:002Weight 1 ε
After correcting for confounders, PB CD341 cell
count remained a significant predictor for collection
CD341 cell count, with the coefficient staying practi-
cally the same. The coefficient for the log(PB CD34)
could be interpreted as indicating that a doubling in
PB CD341 cell count would lead to 20.962 5 1.948-
fold higher collection CD34 levels (95% confidence
interval, 1.93- to 1.97-fold) if weight and WCC re-
mained the same.However, although WCC and weight were inde-
pendent significant predictors, the R2 value only in-
creased from 91.9% to 93.4%, meaning that they
help explain only 1.5% more of the variability in PB
CD341 cell count that was not already explained by
the collection CD341 cell count.
Poor CE Episodes
For all data analyzed, collection episodes were
sorted according to ascending CE; nine out of 1,225
demonstrated a CE\20%when PBCD341 cell count
was .10  106/L. Collection data for these episodes
Figure 6. (A) Relationship between collection CD341 cell count and
PB CD341 cell count for all samples from patients with a diagnosis of
NHL (after logarithmic transformation; y 5 22.6365 1 0.9824x; R2 5
92.1%; P \ .0001). (B) Relationship between collection CD341 cell
count and PB CD341 cell count for all samples from patients with a di-
agnosis of plasma cell dyscrasia (after logarithmic transformation), y 5
22.58171 0.9616x, R25 92.3%, (P\.0001). (C) Relationship between
collection CD341 cells and PB CD341 cells for all samples from patients
with a diagnosis other than plasma cell dyscrasias or NHL (after logarith-
mic transformation; y 5 22.4711 1 0.9173x; R2 5 90.0%; P\.0001).
Figure 7. Boxplots showing median, 10th and 90th percentiles, maxi-
mum, and minimum CE for collections in patients with NHL, MM, and
MDS/MPD. NHL versus MM: P 5 not significant; *NHL versus MDS-
MPD: P 5 .015; **MM versus MDS-MPD: P 5 .019.
770 Biol Blood Marrow Transplant 18:763-772, 2012P. Gambell et al.are presented in Table 5. These episodes were catego-
rized according to the variables investigated (ie,WCC,
mobilization, weight, and diagnosis). Of these vari-
ables, the diagnosis of myelodysplastic syndrome/
myeloproliferative disorder (MDS/MPD), as part of
the ‘‘other’’ diagnosis category, appeared to have a dis-
proportionately high incidence within this poor CE
group. To explore this further, we examined the entire
cohort of collection from patients with MDS/MPD
(n 5 45). In our dataset, this MDS/MPD group com-
prised patients with a diagnosis of MDS (n 5 4),
chronic myelogenous leukemia (n 5 33), or myelofi-
brosis (n 5 8). The comparative data are displayed inboxplots in Figure 7. The median CE for this MDS/
MPD group was significantly reduced compared with
the NHL group (P 5 .015) and MM group (P 5
.019). Notably, none of the nine poor CE collections
demonstrated an elevated serumalbuminor hematocrit
level, factors previously reported to have a negative
effect on CE [25].DISCUSSION
In an attempt to identify factors affecting the abil-
ity of the PB CD341 cell count to predict collection
CD341 cell yield, we investigated the impact of mobi-
lization regimen, patient body weight, PB WCC, and
diagnosis. We undertook a comprehensive analysis of
consecutive collections over a 5-year period.
Our results confirm previous studies that showed
the very good predictive power of PB CD341 cell
count for collectionCD341 cell yield.Overall, a signif-
icant linear relationship was shown between collection
CD341 cell yield and PB CD341 cell count. For all
data analyzed, our median PB CD341 cell count of
21.2  106/L correlated strongly (R2 5 91.9%) with
our median collection CD341 yield of 1.48  106/
kg. Our results show that for all data analyzed, a dou-
bling in PBCD341 cell count would lead to a 20.95935
1.94-fold higher collection CD341 cell count. Based
on this correlation, Table 6 shows the predicted
CD341 cell yield for a given PB CD341 cell count.
A rule of thumb approximation is PB CD341 cells 
0.07 5 CD341 cells. Although a multivariate analysis
identified WCC and weight as possible confounders
in this univariate model that might affect this approx-
imation, they improved the correlation by only 1.5%
on stepwise multivariate analysis (change in R2 from
91.9% to 93.4%).
When analyzing the effect of mobilization regi-
men, excellent correlation was shown between PB
CD341 cell count and collection CD341 cell count
regardless of whether patients were mobilized
with filgrastim 1 chemotherapy or filgrastim alone
Table 6. Predicted CD34+ Cell Yields for Given PB CD34+
Cell Counts
PB CD34+ Cells, 106/L CD34+ Cell Yield, 106/kg
5 0.36
10 0.70
25 1.68
50 3.26
100 6.34
250 15.26
500 29.68
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purpose of this study was not to compare the effective-
ness of mobilization strategies for CD341 cells, our
findings agree with previously reported results demon-
strating the greater effectiveness of chemotherapy-
based regimens [30]. Clearly, factors that influence
physicians’ choice of mobilization regimen would
have affected the observed differences.
When analyzing the effect of patient body weight,
thepredictive ability ofPBCD341 cell count for collec-
tionCD341 cell yield was sustained across the different
patient body weight ranges, including extremes of
weight. A detailed analysis indicates that although sub-
tle differences in themedianPBCD341 cell and collec-
tion CD341 cell counts were seen among the three
weight categories, the correlation did not differ signif-
icantly (R25.90% for all three weight classes). This is
not unexpected given the incorporation of patient body
weight into calculatedproductCD341 cell yield.At our
center, actual bodyweight is used to calculate the prod-
uct CD341 cell content. Incorporation of ideal body
weight merits further investigation, given the reported
impact of ideal body weight and cell dose on hemato-
poietic recovery in some published studies [31,32].
Analysis of PB WCC indicates that the small dif-
ference in median PBCD341 cell count and collection
CD341 cell yield among the three WCC categories
did not affect the predictive ability of PB CD341 cell
count (R2 .90% for all three WCC categories). This
observation is reassuring, given that extreme WCC
values (low or high) is a factor in apheresis machine
collection settings.
Analysis of the effect of diagnosis showed higher
median PB CD341 cell counts and collection
CD341 cell yields in patients with plasma cell dyscra-
sias (MM) compared with NHL and other diagnoses;
however, diagnosis did not affect the predictive ability
of PB CD341 cell count in these three diagnostic co-
horts (R2 $90% for the three diagnoses). Analysis of
MDS/MPDwithin the ‘‘other’’ diagnostic group is dis-
cussed further in the information to follow.
A previous study at our center described poor and
excellent CD34 CE phenomenon as false-negative and
false-positive outcomes [22]. A false-negative result
was described as a good collection when PB CD341
cell count predicted a poor collection CD341 cellyield, and a false-positive result was described as
a poor collection when PBCD34 predicted a good col-
lection CD341 cell yield. It is this false-positive group
of episodes that causes the most trouble for transplan-
tation teams. Often, an unexpected poor collection re-
sults in a subsequent costly collection episode that
might not ordinarily occur. Occasionally, it might re-
sult in inadequate total CD341 cell dose across amobi-
lization regimen, resulting in a second mobilization
episode. Although overall our data support that PB
CD341 cell count is highly predictive of collection
CD341 cell yield, in our false-positive group (ie, unex-
pected poor CE [\20%]), we did identify one group of
patients (MDS/MPD) with a significantly lower CE
value compared with all other groups, indicating that
PB CD341 cell count did not consistently accurately
predict collection CD341 cell yield in this patient pop-
ulation. This finding is not readily explained. Although
the PB CD341 cell count is often high in this group,
why is the CE lower? This phenomenon is not seen
in patients with MM, who also often have a high PB
CD341 cell count. Possible technical influences may
include unclear mononuclear cells and red cell inter-
face layer, resulting in lower CE values in these pa-
tients. Of note, we excluded high serum albumin and
hematocrit levels in this group. We could also specu-
late that biological differences may be influencing
the CE, such as differences in the marrow microenvi-
ronment, therapy (eg, imatinib), or heterogeneity of
the CD341 cell population given that this group rep-
resents disorders of primitive hematopoietic cells (as
opposed to disorders of more mature hematopoietic
cells, such as NHL and MM). Of note, we did not ob-
serve any difference in engraftment kinetics in this
group. Future studies could focus on this group and
more closely examine such variables as circulating
CD341 cell level before mobilization, comparative ef-
fects of filgrastim, major differences in hematocrit, and
variations in the red cell interface.
Other technical issues that have not been investi-
gated in detail here include apheresis machine setup
andmonitoring and the timing of PBCD341 cell anal-
ysis. The true PB CD341 cell count at the time apher-
esis actually commences may differ from the PB
CD341 cell count reported earlier that day. Occasion-
ally, apheresis is started as long as several hours after
PB sampling due to various factors, including aphere-
sis machine availability and central venous access
placement. A delay in starting apheresis should be con-
sidered in cases of unexpected poor CD341 cell yield.
That information was not available in this study. Prob-
lems associated with improper HPC-A processing af-
ter apheresis collection should be considered as well,
including inadequate or excessive centrifugation dur-
ing the volume-reduction step, calculation errors dur-
ing processing, poorly maintained equipment (eg,
scales, centrifuges), and incorrectly programmed
772 Biol Blood Marrow Transplant 18:763-772, 2012P. Gambell et al.autoprocessing equipment. Well-designed and main-
tained quality systems should prevent or at least mini-
mize the likelihood of these technical errors. Given
that all of our processing was in a cGMP environment,
we believe that such issues were of little significance.
We conclude that PB CD341 cell analysis for pre-
diction of HPC-A CD341 cell yield is a powerful tool
and that such factors as mobilization regimen, PB
WCC, and body weight do not influence its reliability.
Diagnosis may contribute to variations in CE, any fur-
ther analysis of this potential phenomenon iswarranted.
Ongoing monitoring of CD341 cell yield is vital, and
unexpected individual CD341 CE outliers warrant
further investigation. Quality assurance with regular
reporting of CE data allows for real-time trend analysis
with an enhanced ability to detect sources of CE vari-
ability and equipment and/or process malfunction.ACKNOWLEDGMENTS
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